GW 501516

GW 501516 (GW 1516) is a PPARδ agonist with an EC50 of 1.1 nM[1].

Product Specifications

CAS Number

[317318-70-0]

Product Name Alternative

GW 1516; GSK-516

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; PPAR

Type

Reference compound

Related Pathways

Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/GW-501516.html

Purity

99.27

Solubility

DMSO : ≥ 100 mg/mL

Smiles

OC(COC1=CC=C(C=C1C)SCC2=C(N=C(S2)C3=CC=C(C=C3)C(F)(F)F)C)=O

Molecular Formula

C21H18F3NO3S2

Molecular Weight

453.50

Precautions

H302, H315, H319, H335

References & Citations

[1]Wei ZL, et al. A short and efficient synthesis of the pharmacological research tool GW501516 for the peroxisome proliferator-activated receptor delta. J Org Chem. 2003 Nov 14;68 (23) :9116-8.|[2]Mosti MP, et al. Effects of the peroxisome proliferator-activated receptor (PPAR) -δ agonist GW 501516 on bone and muscle in ovariectomized rats. Endocrinology. 2014 Jun;155 (6) :2178-89.|[3]Yang X, et al. GW 501516, a PPARδ agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFκB pathway in mice. PLoS One. 2011;6 (9) :e25271.|[4]Chen W, et al. A metabolomic study of the PPARδ agonist GW 501516 for enhancing running endurance in Kunming mice. Sci Rep. 2015 May 6;5:9884.|[5]Ji Y, et al. PPARβ/δ Agonist GW501516 Inhibits Tumorigenicity of Undifferentiated Nasopharyngeal Carcinoma in C666-1 Cells by Promoting Apoptosis. Front Pharmacol. 2018 Jun 28;9:648.